https://pro.boehringer-ingelheim.com/ph/ 2025-10-14T11:53:43+00:00 daily 1.0 https://pro.boehringer-ingelheim.com/ph/cardiovascular/hypertension/telmisartan 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/hypertension/telmisartan/pharmacology 2025-02-03T06:36:46+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/hypertension/telmisartan/safety 2025-02-03T06:46:00+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/hypertension/telmisartan/prescribing-info 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/pharmacists 2025-01-21T12:12:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/pharmacists/metabolic/t2d/lingliptin/linagliptin-drug-interactions 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/pharmacists/metabolic/t2d/lingliptin/linagliptin-contraindication-warning-special-precaution-and-overdosage 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/pharmacists/eLearning 2025-04-03T12:27:26+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular 2025-01-09T10:16:37+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic 2025-02-01T14:02:56+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/terms-use 2025-01-22T15:04:45+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/contact 2025-01-23T06:47:10+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/privacy 2026-01-06T11:01:44+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/resources 2025-01-23T06:53:20+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/all-products 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/cardiovascular-protection 2023-09-22T06:27:24+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/24-hour-bp-control 2023-09-22T06:27:35+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/renal-benefits 2023-09-22T06:27:45+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/quality-and-legacy 2023-10-09T07:49:33+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/dosing-convenience 2023-09-22T06:56:56+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/simplicity 2023-09-14T04:00:51+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/cv-renal-safety 2023-10-09T05:23:49+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/spiolto 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/micardis/cost-effectivess-price-comparison-micardis-twynsta 2025-01-23T08:59:44+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cost-effectivess-price-comparison-micardis-twynsta 2024-07-24T10:40:57+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/jardiance-hf/empagliflozin-jardiances-consistent-cv-and-renal-benefits-hfref 2025-01-10T10:10:30+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/jardiance-hf 2024-07-24T10:34:18+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/jardiance-hf/empagliflozin-jardiance-10mg-improves-quality-life-hfref 2025-01-10T10:10:10+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/dosing-convenience/linagliptin-trajenta-true-convenience-broad-range-patients 2025-01-23T08:44:09+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/resources/cardiovascular 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/resources/metabolic 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/jardiance-hf/jardiance-10mg-safe-heart-failure 2025-01-10T10:09:55+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/safety/noac-safety-clinical-practice-evidence-real-world 2025-01-23T12:39:05+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/cv-renal-safety/carmelina-confirms-long-term-cv-and-renal-safety-linagliptin-trajenta-cv-and-renal 2025-02-01T13:57:32+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/cv-renal-safety/carmelina-trial-summary 2025-02-01T13:54:49+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/video 2025-02-01T14:11:51+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory 2025-01-23T12:56:16+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/clinical-studies 2025-02-01T14:11:00+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/initiation-in-mild-to-moderate-hypertension 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/initiation-in-high-risk-hypertensive-patients 2025-02-01T06:21:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/initiation-in-hypertensive-patients-with-t2d-with-or-without-albuminuria 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/role-of-combination-therapy 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/initiation-in-hypertensive-patients-with-ckd 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/cv-renal-safety/carmrlina-sub-analysis-on-diverse-age-groups 2025-02-01T13:26:00+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/type-2-diabetes-management 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/which-patients-benefit-from-dpp4-monotherapy 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/renal-safety-of-linagliptin-trajenta 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/simplifying-t2d-management 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/linagliptin-and-t2d-patients-undergoing-dialysis 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/what-makes-carmelina-and-carolina-different-vs-other-dpp4i-studies 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/where-do-dpp4-inhibitors-fit-in-t2d-management 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/are-there-data-on-the-risk-of-hypoglycemia-with-dpp4i-such-as-linagliptin 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/linagliptin-trajenta-proven-conisistent-efficacy-regardless-of-renal-function 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empa-kidney-stepping-next-level-chronic-kidney-disease-management 2025-02-01T13:13:56+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empowering-physicians-in-kidney-disease-management 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/chong-hua-hospital-home 2025-01-24T10:20:41+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/type2-diabetes-linagliptin 2025-01-24T10:26:27+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/notre-dame-home 2025-01-24T11:48:40+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryease-use 2025-02-03T13:16:43+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryrenal-benefit 2025-02-03T13:23:48+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/glorycv-benefit 2025-02-03T13:25:39+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryintroduction-video 2025-02-03T13:26:42+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryt2d-treatment-goal 2025-02-03T13:27:33+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/glorymetabolic-benefits 2025-02-03T13:28:22+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/design-recruitment-and-baseline-characteristics-of-the-empa-kidney-study 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin-in-patients-with-ckd 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/sglt2-inhibitor-moa-kidney 2025-02-03T13:18:45+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/which-screening-test-to-use 2025-02-03T13:19:33+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/what-is-a-safe-drop-in-egfr 2025-02-03T13:20:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/ckd-etiologies-and-potential-role-of-sglt2i 2025-02-03T13:21:18+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/why-raas-inhibitors-are-not-enough 2025-02-03T13:22:07+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/update-2023-esh-guidelines-for-the-management-of-arterial-hypertension 2025-02-03T13:22:50+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/conversations-kidney-disease 2025-02-03T13:23:48+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empa-kidney-faqs 2025-02-03T13:25:00+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/md-talks 2025-02-03T13:25:54+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/broadening-horizons-with-empagliflozin 2025-02-03T13:26:36+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/potential-role-of-sglt2s-in-the-upcoming-kdigo-ckd-guidelines 2025-02-03T13:27:38+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/current-and-upcoming-treatment-options-in-ckd-management 2025-02-03T13:28:20+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/prof-groop-empa-kidney-difference-vs-other-CKD-trials 2025-02-03T13:29:54+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/prof-herrington-empa-kidney-trial-results 2025-02-03T13:31:17+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/time-travel-in-crm-travelogue-the-butterfly-Effect 2025-02-03T13:32:09+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empa-kidneys-broad-ckd-population-potential-mechanisms 2025-02-03T13:33:09+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/sglt2i-benefits-from-a-crm-perspective 2025-02-03T13:34:14+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin-in-the-midst-of-ckd-trials 2025-02-03T13:35:16+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/prime-summit-2024 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance 2025-01-24T12:28:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/adverse-events 2024-06-13T07:43:41+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empowering-physicians-in-kidney-disease-management-webinar-9 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/quality-and-legacy 2025-01-24T12:53:05+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/make-10-happen-thank-you-page 2025-01-24T13:03:52+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/how-effective-empagliflozin-or-without-arni 2025-01-24T13:13:58+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/how-confident-are-you-start-empagliflozin-non-t2d-hf-patients 2025-01-24T14:49:44+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/renal-efficacy-and-safety-empagliflozin-hf 2025-01-24T15:11:51+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflammation/nintedanib/ssc-ild/data-ra-ild-inbuild-trial-subgroup 2025-01-24T15:23:32+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflammation/nintedanib/ssc-ild/ild-risk-factors-ra-patients 2025-01-24T15:25:40+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflammation/nintedanib/ssc-ild/managing-ctd-ild-patients 2025-01-24T15:32:26+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflammation/nintedanib/ssc-ild 2024-12-26T09:42:59+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflammation/nintedanib/ssc-ild/initiating-treatment-ssc-ild 2025-01-24T15:36:42+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/elearning/with-linagliptin-one-dose-fits-all 2025-01-24T15:39:18+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/elearning/are-all-dpp4i-equal-in-terms-of-evidence 2025-01-24T15:06:35+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/elearning/prof-jacob-evidence-based-medicine 2025-01-24T15:04:30+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/safety/expert-video-series-carolina-only-cvot-active-comparator-glimepiride 2025-02-04T05:06:09+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/safety/expert-video-series-what-makes-carmelina-stand-out-vs-other-dpp4i-cvots 2025-02-04T05:06:02+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/reversibility/reversibility-campaign-video 2025-01-24T14:39:03+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/dosing-convenience/expert-video-1-not-all-dpp4i-are-same-dosing-simplicity 2025-01-24T13:55:17+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/efficacy/patient-story-1 2025-01-24T13:45:25+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/trajenta/ndpp4-prof-ted-wu-interview-video-broad-range-patients 2025-02-03T15:22:01+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/trajenta/ndpp4-prof-ted-wu-interview-video-efficacy 2025-02-03T15:22:38+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/empagliflozins-proven-efficacy-and-safety-hf-patients-or-without-t2d 2025-01-27T05:22:33+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/safety/re-ly-trial-landmark-study-cardiology-new 2025-01-27T05:35:37+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/safety/gloria-a-pase-3-results 2025-01-27T05:41:27+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/safety/patient-story-2 2025-01-27T05:43:22+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/empagliflozins-robust-renal-data-full-spectrum-hf 2025-01-27T05:45:14+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/empagliflozin-has-consistent-cv-benefits-full-spectrum-hf 2025-01-27T05:46:40+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/empagliflozin-jardiance-improves-qol-hf-patients 2025-01-27T05:47:52+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/initiating-empagliflozin-hf-patients-low-egfr 2025-01-27T05:50:48+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/safety/ask-expert-prof-obrien-renal-safety 2025-02-04T05:05:55+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/safety/ask-expert-prof-obrien-cv-safety 2025-02-04T05:05:44+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/efficacy/ask-expert-prof-obrien-efficacy 2025-01-27T05:59:35+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/dosing-convenience/ask-expert-prof-obrien-dosing-convenience 2025-01-27T07:48:43+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/simplicity/ask-expert-prof-obrien-broad-range-patients 2025-01-27T06:21:05+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-guidelines-hfref 2025-01-27T06:26:18+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic-hf/empagliflozin/experts-video/lets-talk-impact-sglt2i-trials-hfpef 2025-01-27T06:30:50+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/simplicity/limited-kidney-video-prof-roger-chen 2025-01-27T07:02:33+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/cv-renal-safety/carmelina-cvot-video 2025-02-01T13:11:20+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/simplicity/pcdr-esteban-jodar-06-trajenta-ph-video 2025-01-27T07:10:58+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/micardis/treat-hypertension-power-protection-convenience 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/jardiance-hf-emotional-patient-video 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/makati-medical-center-home 2025-01-27T07:13:34+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/saint-lukes-medical-center-qc-home 2025-01-27T07:15:39+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/university-santo-tomas-hospital-home 2025-01-27T07:16:39+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/saint-lukes-medical-center-bgc-home 2025-01-27T07:17:32+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/philippines-heart-center-home 2025-01-27T07:18:30+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/lung-center-philippines-home 2025-01-27T07:29:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflammation/nintedanib 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic-hf/empagliflozin/experts-video 2025-01-24T14:26:52+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryrenal-benefit-new 2025-02-03T14:44:00+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/lung-center-philippines-medicine-assistance 2024-12-13T07:43:46+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/isap-partner-hospitals-as-of-july-2024 2025-02-01T11:19:28+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryintroduction-video-new 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/ptphf-bione-main-landing-page 2025-01-24T14:56:07+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/lets-talk-expert-videos-bione-page 2025-01-24T14:41:43+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/integrated-special-access-program 2025-01-24T15:04:40+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/de-la-salle-university-medical-center 2025-01-24T15:06:43+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/de-la-salle-university-medical-center/dlsumc-process-flow-for-isap-diagnostic-hrct-and-medicine-assistance 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/lets-talk-expert-videos-bione-page/guidelines-recommend-the-4-pillar-approach-in-managing-HFrEF 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/trajenta/linagliptin-cme-modules 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/glorymetabolic-benefits-new 2025-02-03T14:46:43+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/making-impact-hf-bione-webinar-episode-1-post-event-video 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryt2d-treatment-goal-new 2025-02-03T14:50:07+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/making-impact-hf-bione-webinar-episode-2-post-event-videos 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryease-use-new 2025-02-03T14:50:58+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/glorycv-benefit-new 2025-02-03T14:51:37+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/important-update-regarding-isap-diagnostic-support 2025-01-24T15:15:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/lets-talk-expert-videos-bione-page/from/prof/andrew/coats 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/philippines-general-hospital-home 2025-02-01T12:39:42+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/gloryintroduction-video1 2025-02-03T13:18:41+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/glyxambi/metabolism/profile-info 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/dabigatran-etexilate/prescribing-information/idarucizumab-praxbind-prescribing 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/prescribing-information/empagliflozin-metformin-hci-jardiance-duo 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/prescribing-information/linagliptin-trajenta-prescribing-information 2025-03-14T05:19:42+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/prescribing-information/linagliptin-metformin-hcl-trajenta-duo-prescribing 2025-01-24T15:38:31+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic-hf/empagliflozin/prescribing-information/empagliflozin-jardiance-prescribing-information-test 2025-02-11T13:19:57+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/prescribing-information/telmisartan-micardis-prescribing-information 2025-02-25T06:26:17+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic-hf/empagliflozin/prescribing-information/empagliflozin-metformin-hci-jardiance-duo 2025-05-14T09:37:16+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/prescribing-information/telmisartan-hctz-micardis-plus-prescribing 2025-02-25T06:26:41+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/oncology/giotrif/prescribing-information 2025-01-24T11:59:37+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/spiolto/prescribing-information 2025-01-24T12:01:52+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/prescribing-information 2025-02-25T06:26:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/prescribing-information/telmisartan-amlopidine-besilate-twynsta 2025-02-25T06:27:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/actilyse/dosing 2024-08-01T06:37:34+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/actilyse/efficacy 2025-01-24T12:25:55+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/actilyse 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflammation/nintedanib/expert-view 2024-08-13T08:06:38+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/making-impact-hf-bione-webinar-episode-1-post-event-videos 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/treatment-plan-jardiance-daily-oral 2025-01-24T13:11:15+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/makati-medical-center-diagnostic-support 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/benefits-for-hhf 2025-01-24T14:19:58+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/jardiance-treatment-plan 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/jardiance-first-quiz-finish 2025-01-24T15:04:50+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiometabolic/events/prime-summit-3-2024 2025-01-24T15:11:11+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video 2025-05-05T12:03:37+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/benefits-for-cv-death 2025-02-03T07:23:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/reduce-the-risk-of-cv-death-empagliflozin 2025-01-24T15:29:01+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/safety 2025-01-24T15:35:10+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/masterclass-cardiovascular 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/reduce-the-risk-of-cv-death-or-hhf-empagliflozin 2025-01-24T15:36:57+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/benefits-for-cv-death-or-hhf 2025-01-24T15:43:58+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/elearning 2025-01-24T15:46:55+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/reduce-the-risk-of-hhf-empagliflozin 2025-01-24T15:50:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiometabolic 2024-08-12T18:42:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiometabolic/events 2024-08-12T18:43:39+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/actilyse/guidelines 2025-01-24T12:48:09+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/actilyse/safety 2025-01-24T12:50:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/actilyse/efficacy/test-page-banner 2025-01-24T16:05:36+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/heart-failure-1 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/heart-failure-2 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/hf-esc-2023-guideline-update-with-prof-theresa-mcdonagh 2025-02-01T06:46:41+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/cv-protection 2024-12-13T06:54:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/inflamation/nintedanib/coll4b 2024-09-13T09:52:38+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/resources/inflammation 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin-linagliptin 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin-linagliptin/efficacy 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/spiolto/tiotropium-olodaterol-spiolto-respimat-from-good-to-great 2025-01-20T04:37:37+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/ildtalks-ppf-in-ctd-ild-nintedanib-and-ctd-treatments 2025-02-03T15:32:59+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/products/jardiance/all-specialties/upcoming-events/cardiology/hf-webinar 2025-09-30T15:03:04+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/jardiance-duo 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/products/jardiance/all-specialties/past-events/cardiology/prime-summit-2-day-1 2025-01-24T16:41:02+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/products/jardiance/all-specialties/past-events/cardiology/prime-summit-2-day-2 2025-01-24T16:45:49+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory/ofev/important-update-regarding-isap-medicine-assistance 2025-01-22T05:16:22+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/ropu-esc-hfa-nt-probnp-thresholds-for-new-hf-diagnosis 2025-01-24T16:47:21+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/ropu-screening-for-cardiovascular-kidney-metabolic-syndrome 2025-01-22T05:03:31+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/ropu-how-do-i-diagnose-and-manage-hfpef 2025-01-22T05:03:58+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/ropu-hfpef-scoring-and-interpretation 2025-01-22T05:04:05+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/ropu-comparative-sglt2i-rwe 2025-01-22T05:04:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/ropu-cardiorenal-effects-of-empagliflozin-after-ami 2025-01-22T05:04:19+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-green-2-importance-of-egfr-and-uacr-screening 2025-02-03T15:05:37+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-jarvis-1-tips-for-sip-when-initiating-sglt2i-in-t2d 2025-02-03T15:05:06+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-wanner-1-ero-renal-data 2025-02-03T15:05:03+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory-specialty/ofev/philippine-heart-center-ild-clinic 2025-02-03T08:20:54+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin-linagliptin/experts-videos/early-intensification-with-combination 2025-03-14T05:29:49+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory-specialty/ofev/multi-disciplinary-discussion-case-sharing-from-st-lukes-medical-center-ild-team 2025-01-09T09:10:31+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory-specialty/ofev/multi-disciplinary-discussion-case-sharing-from-philippine-heart-center-ild-team 2025-01-09T09:11:23+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory-specialty/ofev/multi-disciplinary-discussion-case-sharing-from-makati-medical-center-ild-team 2025-01-09T09:12:56+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin-linagliptin/experts-videos 2025-02-03T10:37:46+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory-specialty/ofev/multi-disciplinary-discussion-case-sharing-from-chong-hua-hospital-ild-team 2025-01-09T09:13:51+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory-specialty/ofev/multi-disciplinary-discussion-case-sharing-from-university-of-santo-tomas-ild-team 2025-01-09T09:15:31+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin-linagliptin/experts-videos/advantages-of-empa-and-lina-in-glyxambi 2025-03-14T05:30:52+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance-2025 2025-01-30T04:29:01+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance-2025/take-a-sip-prof-green-2-importance-of-egfr-and-uacr-screening-2025 2025-02-07T10:34:36+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance-2025/take-a-sip-prof-jarvis-1-tips-for-sip-when-initiating-sglt2i-in-t2d-2025 2025-02-07T10:34:50+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/sip-campaign-guidance-2025/take-a-sip-prof-wanner-1-ero-renal-data-2025 2025-02-07T10:35:05+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/prof-wanner-why-early-kiney-screening-by-pcp-2025 2025-02-01T12:01:28+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/take-a-sip-prof-green-2-importance-of-egfr-and-uacr-screening-2025 2025-01-30T04:28:10+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/dr-brendon-26-6-delay-to-kidney-replacement-therapy-2025 2025-01-30T04:28:17+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/hcps-role-in-ckd-management-when-to-refer-2025 2025-01-30T04:30:06+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/pcps-role-in-dkd-management-and-when-to-refer-to-endocrinologist-2025 2025-01-30T04:30:14+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolism/jardiance/what-does-kidney-function-preservation-in-empa-kidney-mean-to-you-2025 2025-01-30T04:30:21+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/heart-diseases/actilyse/alteplase-actilyse-20mg-and-50mg-powder-iv-infusion 2025-02-25T06:21:54+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic-hf/empagliflozin/prescribing-information/empagliflozin-metformin-hci-jardiance-duoo 2025-01-02T06:08:21+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/prescribing-information/linagliptinmetformin-hcl-trajenta-duo-now-bottles 2025-05-14T09:36:50+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/respiratory-specialty/ofev 2025-01-09T09:26:34+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/empagliflozin-jardiance-prescribing-Information 2025-02-25T05:04:56+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/telmisartan-micardis-prescribing-Information 2025-03-14T08:17:20+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/linagliptin/linagliptin-trajenta-prescribing-Information 2025-03-17T16:11:41+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/safety-of-empagliflozin-linagliptin-glyxambi-in-t2d 2025-02-01T06:37:11+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/optimal-treatment-in-t2d-with-empagliflozin-Linagliptin-glyxambi 2025-02-01T06:37:20+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/early-control-in-t2d-with-empagliflozin-linagliptin-glyxambi 2025-02-01T06:44:33+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/importance-of-compliance-in-t2d 2025-02-01T06:38:38+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/unique-combination-of-empagliflozin-and-linagliptin-in-t2d 2025-02-01T06:38:49+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/achieve-early-optimal-control-in-t2d-with-empagliflozin-linagliptin-glyxambi 2025-02-01T06:39:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/what-is-the-importance-of-compliance-in-t2d-management 2025-02-01T06:39:50+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/how-a-combination-of-empagliflozin-and-linagliptin-unique-in-t2d 2025-02-01T06:39:56+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/why-early-glycemic-control-in-important-in-t2d 2025-02-01T06:40:05+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/how-does-a-fixed-dose-combination-drug-aids-in-treatment-compliance 2025-02-01T06:40:13+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/advantages-of-empagliflozin-linagliptin-in-t2d 2025-02-01T06:40:23+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/glyxambi/advantages-of-fdc-in-t2d-management 2025-02-01T06:34:24+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/telmisartan/24-hour-bp-control/why-is-it-important-to-address-hypertension-in-its-early-stages-what-is-the-role-of-telmisartan-in-this-subgroup-of-patients-by-prof-thomas-unger 2025-01-27T11:22:08+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic-hf/empagliflozin/prescribing-information/empagliflozin-jardiance-prescribing-information 2025-03-14T08:14:58+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/pharmacists/eLearning/role-of-pharmacists-in-next-generation-care-for-hypertension-by-jardine-sta-ana-md-pafp 2025-02-01T06:19:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/hf-video-prof-melanie-davies-jardiance-safety-for-hf-patients-with-t2 2025-05-05T11:50:18+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/hf-video-prof-sarah-jarvis-empowering-pcps-in-hf 2025-05-05T11:49:50+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/hf-video-prof-sarah-jarvis-capturing-hf-patients-early-in-the-hospital 2025-05-05T11:48:45+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/hf-video-prof-roger-chen-importance-of-catching-hf-patients-early-in-hospital 2025-05-05T11:58:31+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/what-differentiates-empagliflozin-from-other-generic-sglt2is 2025-05-05T11:58:45+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/empagliflozin-to-start-treatment-management 2025-05-05T11:59:00+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-sarah-jarvis-on-empagliflozin-as-crm-medication 2025-05-05T11:56:04+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-sarah-jarvis-on-early-initiation-of-empagliflozin 2025-05-05T11:55:49+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-roger-chen-on-empagliflozin-as-crm-medication 2025-05-05T11:55:35+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-roger-chen-on-early-initiation-of-empagliflozin 2025-05-05T11:55:22+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-melanie-davies-on-empagliflozin-as-crm-medication 2025-05-05T11:55:07+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-melanie-davies-t2d-guidelines-recommendation 2025-05-05T11:54:03+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-melanie-davies-on-early-initiation-of-empagliflozin 2025-05-05T11:52:19+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/crm-symposium-2025/a-decade-of-protection-celebrating-10-years-of-easy-choice-for-protection 2025-03-28T05:39:15+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/crm-symposium-2025/breaking-the-silos-in-cardio-renal-metabolic-disease-care-specialist-focus-on-heart-failure 2025-05-12T12:03:05+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/crm-symposium-2025/kidneys-empowered-transforming-ckd-and-crm-care 2025-07-09T20:16:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/experts-video-prof-zieroth-starting-on-empa-for-t2d-patients-to-address-hf-risk 2025-05-16T11:04:57+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/expers-video-prof-zieroth-value-of-gdmt-to-achieve-outcomes-in-crm 2025-05-16T11:05:12+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/experts-video-prof-zieroth-addressing-hurdles-in-adopting-crm-management 2025-05-16T11:05:28+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/experts-video-prof-zieroth-adhering-to-early-and-sustained-treatment 2025-05-16T11:05:44+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/prof-januzzi-snippet-how-safe-of-empagliflozin-jardiance-in-hfref 2025-05-16T11:06:01+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/metabolic/empagliflozin/experts-video/what-is-the-mechanism-of-jardiance-in-hf-prof-januzzi 2025-05-16T11:06:18+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse/stroke 2025-06-24T14:08:16+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse/stroke/administration 2025-07-03T08:23:21+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse/stroke/safety-profile 2025-06-26T12:59:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse/stroke/efficacy 2025-06-25T13:59:11+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse/stroke/video-for-preparation-and-administration 2025-06-26T13:01:19+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse/stroke/efficiency 2025-06-26T13:00:53+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse/stroke/resources 2025-06-25T13:54:47+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cardiovascular/metalyse 2025-06-20T10:42:01+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/cvm-congress-2024 2024-12-11T09:56:29+00:00 0.5 https://pro.boehringer-ingelheim.com/ph/crm-symposium-2025 2025-03-28T05:00:35+00:00 0.5